Healthcare > Pharmaceuticals & Biotechnology
•2430 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2430)
| Company | Market Cap | Price |
|---|---|---|
|
TARA
Protara Therapeutics, Inc.
TARA-2.00 is a cell therapy platform, representing the company’s lead product modality.
|
$209.91M |
$5.44
+6.04%
|
|
CPMV
Mosaic ImmunoEngineering Inc.
Lead oncology candidate MIE-101 defines CPMV's core product focus in cancer therapy.
|
$208.72M |
$0.52
|
|
CRGX
CARGO Therapeutics, Inc. Common Stock
CRGX's core offerings are oncology CAR-T therapies (firi-cel, CRG-23), placing it in Biotech - Oncology.
|
$206.13M |
$4.47
|
|
SLGL
Sol-Gel Technologies Ltd.
Proprietary microencapsulation drug-delivery platform is a core technology Sol-Gel uses to formulate topical therapies.
|
$205.79M |
$74.82
-0.66%
|
|
CRBU
Caribou Biosciences, Inc.
Company is developing gene-editing gene therapy platforms (CRISPR-based chRDNA) for therapeutic applications.
|
$205.63M |
$2.21
+2.56%
|
|
LFCR
Lifecore Biomedical, Inc.
Lifecore is a pure-play CDMO focused on sterile injectable drug development and manufacturing.
|
$201.57M |
$5.39
+3.65%
|
|
ADAG
Adagene Inc.
Core focus on monoclonal antibody therapeutics (ADG126 and related SAFEbody-based antibodies).
|
$195.03M |
$3.79
-8.57%
|
|
PLX
Protalix BioTherapeutics, Inc.
Protalix manufactures recombinant proteins/enzymes (e.g., Elelyso, Elfabrio) using its plant-based ProCellEx system.
|
$186.58M |
$2.31
+0.43%
|
|
CRBP
Corbus Pharmaceuticals Holdings, Inc.
Corbus's pipeline is focused on oncology assets (CRB-701 and CRB-601) representing biotech oncology products.
|
$185.89M |
$10.59
+4.39%
|
|
HRTX
Heron Therapeutics, Inc.
Biochronomer drug-delivery technology is a platform enabling extended-release formulations across Heron's products.
|
$183.36M |
$1.00
+6.91%
|
|
SABS
SAB Biotherapeutics, Inc.
Company focuses on immunology therapeutics using DiversitAb platform to generate fully human polyclonal antibodies.
|
$183.29M |
$3.86
-1.53%
|
|
RNAC
Cartesian Therapeutics, Inc.
Lead platform is an autologous cell therapy using mRNA CAR-T, a direct cell-therapy product line.
|
$183.07M |
$7.03
+10.19%
|
|
MIST
Milestone Pharmaceuticals Inc.
Milestone's lead candidate etripamil is a cardiovascular drug developed for PSVT and AFib-RVR.
|
$178.86M |
$2.11
+0.96%
|
|
BDTX
Black Diamond Therapeutics, Inc.
BDTX operates as a biotechnology company focused on oncology therapeutics, i.e., Biotech - Oncology.
|
$174.34M |
$3.07
+5.14%
|
|
VXRT
Vaxart, Inc.
VXRT directly develops and advances vaccines (norovirus, COVID-19, avian influenza) using its VAAST oral vaccine platform.
|
$170.96M |
$0.75
|
|
ABOS
Acumen Pharmaceuticals, Inc.
Sabirnetug is a recombinant humanized IgG2 monoclonal antibody targeting soluble AßOs.
|
$170.82M |
$2.84
+5.58%
|
|
REPL
Replimune Group, Inc.
Replimune is oncology-focused biotech developing oncolytic immunotherapies.
|
$170.22M |
$2.17
-0.91%
|
|
TLSA
Tiziana Life Sciences Ltd
TLSA's lead product Foralumab is a fully human monoclonal antibody therapeutic, placing the company in Monoclonal Antibody Therapeutics.
|
$169.24M |
$1.25
-7.09%
|
|
TNXP
Tonix Pharmaceuticals Holding Corp.
TNX-102 SL is Tonix's lead oral small-molecule drug for fibromyalgia (cyclobenzaprine HCl sublingual), a direct product the company develops and plans to bring to market.
|
$164.64M |
$13.96
-1.17%
|
|
QTRX
Quanterix Corporation
Offers contract research services via its Accelerator Lab, aligning with CRO-type activities.
|
$163.49M |
$3.49
+2.65%
|
|
AGEN
Agenus Inc.
Agenus' core focus is oncology with immunotherapy approaches (BOT/BAL) in MSS CRC, supporting Biotech - Oncology.
|
$162.90M |
$4.78
+3.02%
|
|
GALT
Galectin Therapeutics Inc.
Lead cancer therapy program belapectin demonstrates oncology-focused Biotech activity and immuno-oncology potential.
|
$157.96M |
$2.44
+8.19%
|
|
MOLN
Molecular Partners AG
Core focus on oncology therapeutics built on the DARPin platform.
|
$157.26M |
$4.29
+2.63%
|
|
TKNO
Alpha Teknova, Inc.
Teknova provides GMP-grade manufacturing for clinical-relevant reagents and custom solutions, aligning with contract manufacturing services.
|
$156.84M |
$2.95
+10.07%
|
|
IMDX
Insight Molecular Diagnostics Inc.
IMDX maintains an oncology pipeline (DetermaIO, DetermaCNI), placing it in Biotech - Oncology.
|
$156.84M |
$5.54
+1.19%
|
|
RCEL
AVITA Medical, Inc.
RECELL/autologous cell suspension represents a cell-therapy platform within regenerative medicine.
|
$156.73M |
$5.13
+2.81%
|
|
BMEA
Biomea Fusion, Inc.
Direct product category: Biomea Fusion is developing oral small molecule therapeutics, including icovamenib and BMF-650.
|
$156.26M |
$2.21
+14.25%
|
|
THTX
Theratechnologies Inc.
EGRIFTA WR and TH1902 are peptide-based therapeutics, representing Theratechnologies' core peptide therapeutics business.
|
$155.87M |
$3.39
|
|
SPRO
Spero Therapeutics, Inc.
Tebipenem HBr is an oral small-molecule antibiotic, which is the lead product and central to Spero’s current business focus.
|
$154.93M |
$2.75
+2.61%
|
|
ORMP
Oramed Pharmaceuticals Inc.
Oramed's POD platform constitutes the core drug-delivery technology enabling oral administration of therapeutic proteins (e.g., oral insulin).
|
$154.43M |
$3.88
+0.52%
|
|
SAVA
Cassava Sciences, Inc.
Direct product category: simufilam is developed as an oral small-molecule therapeutic.
|
$154.10M |
$3.23
+1.10%
|
Showing page 15 of 25 (2430 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
